SCHEMBL5217595

SCHEMBL5217595

C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]2Cc3cc(Cl)cnc3N21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.43
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
RET P07949 1/20 0.38
PIK3CA P42336 2/20 0.36
PIK3R1 P27986 1/20 0.36
NR3C1 P04150 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
GABRA5 P31644 1/20 0.36
LMNA P02545 1/20 0.36
CACNB4 O00305 1/20 0.35
CACNA1A O00555 1/20 0.35
CACNA1G O43497 1/20 0.35
CACNG3 O60359 1/20 0.35
CACNA1F O60840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223404 0.90 GPR119 (0.46) GPR119PSEN1PSEN2APH1BNCSTN
SCHEMBL5223038 0.88 GPR119 (0.43) GPR119RETPIK3CAPIK3R1LMNA
SCHEMBL5221677 0.87 GPR119 (0.43) GPR119RETPIK3CAPIK3R1FNTA
SCHEMBL5218609 0.87 GPR119 (0.43) GPR119RETPIK3CAPIK3R1AKT1
SCHEMBL5219445 0.87 GPR119 (0.43) GPR119PIK3CAPIK3R1AKT1MTOR
SCHEMBL5221125 0.87 GPR119 (0.43) GPR119RETPIK3CAPIK3R1FNTA
SCHEMBL5217292 0.85 GPR119 (0.48) GPR119PIK3CAAKT1MTOR
SCHEMBL5218017 0.85 GPR119 (0.46) GPR119PIK3CAPIK3R1AKT1MTOR
SCHEMBL5216925 0.85 GPR119 (0.43) GPR119RETPIK3CAPIK3R1AKT1
SCHEMBL5216941 0.82 GPR119 (0.38) GPR119PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641796-B1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY HOFFMANN LA ROCHE (CH) 2007-06-06 EP disclosed
US-7208494-B2 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
EP-1641796-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2006-04-05 EP disclosed
US-20050026925-A1 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. 2005-02-03 US disclosed
WO-2005000849-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026925-A1 5HT2c receptor agonists HTR2C, HTR2A, HTR5A GPR119 17/4885PSEN1 3280/4885PSEN2 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.